Dermira (DERM) Climbs 48% After Reporting Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis

March 18, 2019 7:06 AM

Dermira (NASDAQ: DERM) Climbs 48 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found